I agree with the previous suggestions. This being Phase I study, you must include a summary of adverse events (grades 3, 4, and 5). I generally include relevant "new clinical and nonclinical studies" from the literature so the reviewers know what we are doing. List any deviation from the protocol during the study or any foreseeable future plans. I am sure you must be familiar with it, but just in case, the submission date is due within 60 days of the anniversary date that the application went into effect. I hope this helps.
Israr
------------------------------
Israr Ansari PhD, MS, RAC
Sr. Scientist - Clinical Trials
------------------------------
Original Message:
Sent: 02-Dec-2021 23:05
From: Anonymous Member
Subject: IND annual report question
This message was posted by a user wishing to remain anonymous
Hi,
I have a question about US IND annual report. Our company recently completed a phase I clinical trial, and the CSR will be finalized soon.
Do we still need to submit an annual report to the FDA next year? and when can we stop submitting the annual report?
Thanks a lot!